Navigation Links
Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
Date:5/8/2008

welcome additions to the treatment options currently available for improving patient care."

Schering-Plough acquired asenapine in November 2007 through its combination with Organon BioSciences, which developed the investigational antipsychotic agent. The Food and Drug Administration is reviewing a new drug application (NDA) for asenapine in the treatment for schizophrenia and acute manic or mixed episodes associated with bipolar I disorder. The asenapine Olympia clinical trial program thus far has involved over 3,000 patients and has included bipolar mania and acute schizophrenia trials.

"Based on results from the Olympia trial program, we believe asenapine has the potential to address a clinically important unmet need for patients with schizophrenia and bipolar disorder," said Robert J. Spiegel, M.D., Chief Medical Officer and Senior Vice President, Schering-Plough Research Institute.

Olympia Data: Bipolar I Disorder

The bipolar I disorder program includes two placebo- and active-controlled, three-week trials followed by an extension study totaling one year of treatment involving nearly 1,000 patients with bipolar I disorder. Treatment response was measured using the Young Mania Rating Scale (YMRS) score, an 11-item scale used to evaluate manic symptoms.

In the trials, both asenapine and the active-control drug olanzapine* produced greater mean reductions in YMRS total scores versus placebo after three weeks of treatment. Asenapine produced 13- and 14-point reductions in the YMRS total score from baseline to day 21 (P<0.05 versus placebo; olanzapine was also demonstrated to be statistically superior to placebo; there was no direct comparison between asenapine and olanzapine). In a 9-week extension of the 3-week trials, asenapine was found to be noninferior to olanzapine on the primary efficacy measure, change in YMRS.

The overall incidence of treatment-related adverse events (AEs) in the trials was 60.8 percent in the asena
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
3. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
4. New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... SAN DIEGO , Dec. 17, 2014 ... PHIA) and Volcano Corporation (NASDAQ: VOLC ), a ... applications, today announced that they have entered into a definitive ... tender offer to acquire all of the issued and outstanding ... total equity purchase price of USD 1 billion (approx. EUR ...
(Date:12/17/2014)... HOLBROOK, N.Y. , Dec. 17, 2014 /PRNewswire/ ... that The Depository Trust Company (DTC) has made ... the Deposit Chill on the Company,s stock effective ... of Northstar,s common stock for depository and book ... and the Company is now once again fully ...
(Date:12/17/2014)... 17, 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... Trademark Office (USPTO) has issued a key patent ... immunotherapeutic vaccine targeting six tumor antigens that are ... Patent No. 8,871,211, which issued October 28, 2014, ... a dendritic cell composition comprising peptide epitopes of ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... Jan. 22 Protalix,BioTherapeutics, Inc. (Amex: PLX ... concept results in an animal study conducted as ... is being conducted under the agreement the Company ... the technology transfer,arm of the Hebrew University of ...
... approved to reduce both A1C and LDL cholesterol, ... Inc.,announced that the United States Food and Drug ... glycemic control,(measured as hemoglobin A1C) in adults with ... or insulin, either alone or in,combination with other ...
Cached Medicine Technology:Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study 2Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study 3Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 2Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 3Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 4Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 5Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 6Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 7
(Date:12/21/2014)... December 21, 2014 As testosterone ... heart attacks, stroke and blood clots from using testosterone ... a new study shows that the male hormone testosterone ... In a study published in the Proceedings of the ... Amos-Landgraf examined a group of male rats with naturally ...
(Date:12/20/2014)... 2014 BambooIndustry.com is a ... business has announced its bamboo flooring promotion for ... material from certified suppliers, and offers the best ... In the current promotion, all customers can enjoy ... they say they know BambooIndustry.com from press releases. ...
(Date:12/20/2014)... 20, 2014 DePuy Pinnacle hip ... version of the artificial hip system was defectively ... federal courts, Bernstein Liebhard LLP reports. According to ... Superior Court on December 2nd, counsel in 10 ... of plaintiffs on November 19, 2014, with depositions ...
(Date:12/20/2014)... Angeldress.co.uk, the distinguished wedding dress manufacturer and retailer, has ... company has recently updated its official blog with the ... Angeldress Blog has recommended some new designs ... itself in offering a huge selection of elegant products ... outfits are very carefully selected based on the design ...
(Date:12/20/2014)... 20, 2014 Developers of FCPX ... a new plugin for Final Cut Pro X entitled ... Volume 5 allows users to create hand drawn text ... Christina Austin, CEO of Pixel Film Studios. “TranSlice Volume ... while maintaining an easy to use interface.” , TranSlice ...
Breaking Medicine News(10 mins):Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2
... Brings Pro-Quality Services to the Public, ATLANTA, ... Arthur,Blank,s management and investment company is about to ... Centers -- that will bring,professional-grade physical therapy and ... (Photo: http://www.newscom.com/cgi-bin/prnh/20070912/DCW010LOGO ) AMB ...
... BASKING RIDGE, N.J., Sept. 12 Hooper Holmes,Inc. (Amex: ... Chris Behling as,President of the Company,s new Health & ... July 2006 as Senior Vice President,and Business Development Officer, ... new opportunities, including the wellness,market. The division has made ...
... given more certified sick leave by male doctors compared with ... doctors, a University of Liverpool study has revealed. , The ... that male GPs are more likely to give male patients ... work compared with female patients certified by female doctors. ...
... Sept. 12 ReBuilder Medical,Technologies, Inc. today reported ... its international customer base to include England, Canada, ... ) "These sales began to come in ... who experienced success using the ReBuilder System(R). Through,word ...
... Brings Infringement Action, LIVINGSTON, N.J., Sept. 12 ... announced that on August,24, 2007 it commenced a ... United States District Court for the District of ... neither its Single Tooth,Anesthesia (STA(TM)) system nor its ...
... for an easy way to,power up fall and winter ... favorite is a smart choice when it comes to ... The National Barley Foods Council reminds consumers that ... economical ingredient with a,nutty flavor and pleasant chewy texture, ...
Cached Medicine News:Health News:Atlanta Falcons Physical Therapy Centers Set to Launch This Fall 2Health News:Atlanta Falcons Physical Therapy Centers Set to Launch This Fall 3Health News:Hooper Holmes Names Chris Behling President of Health & Wellness Division 2Health News:Hooper Holmes Names Chris Behling President of Health & Wellness Division 3Health News:More sick leave given to men by male GPs compared with female counterparts 2Health News:ReBuilder Medical Technologies, Inc. Reports International Sales Expansion 2Health News:ReBuilder Medical Technologies, Inc. Reports International Sales Expansion 3Health News:ReBuilder Medical Technologies, Inc. Reports International Sales Expansion 4Health News:Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System 2Health News:Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System 3Health News:Harness the Power of Grains With Barley 2Health News:Harness the Power of Grains With Barley 3
The 40D is ideal for pediatric ophthalmoscopy and other examinations requiring expansive fundus visibility. Alternatively, this lens may be used at the slit lamp biomicroscope to provide an extremely...
This excellent mid-power lens provides medium field and magnification, with an ideal diameter for grip andmanipulation in the orbital area....
The 15D provides high magnification along with an optimized working distance from the cornea. With its 4.11x magnification it is also well suited for disc and macular observation....
The Professional ophthalmoscope has been designed to ensure ultimate control. Lenses, graticules and filters can all be introduced at the touch of a fingertip without the need to pull away from the p...
Medicine Products: